
July marks record 24,500 tech job cuts: TCS, Microsoft, Intel hit hardest
The month began with Microsoft announcing that it was laying off nearly four per cent of its global workforce across teams and role types. These job cuts are said to have impacted Microsoft staff across geographies. In less than a fortnight, another tech major, Intel, announced that it was laying off more than 5,000 employees across four states in the US. Closer to home, Tata Consultancy Services (TCS) announced that it was sacking over 12,000 of its staff.
While these job cuts in July largely impacted the workforce in the US, on July 27, TCS claimed that it would be axing two per cent of its global workforce, which would spell job loss for over 12,000 employees. The announcement by TCS comes at a time when the company has been battling allegations of forced resignations following its new 'bench policy' that limited an employee's bench duration to 35 days annually.
Bench usually refers to the time when an employee is not actively assigned to a client project but stays on a company's payroll. Based on TCS' bench policy, employees were expected to spend four to six hours daily upskilling themselves through internal platforms with strict work from the office. Experts claimed that the policy puts the onus on employees to proactively seek new projects through the Resource Management Group. Reportedly, these long periods without allocation could likely impact their compensation, growth, employment continuity, and other opportunities.
In response to the job cuts, TCS claimed that it is on a journey to become a future-ready organisation. Their vision includes strategic initiatives on multiple fronts, investments in new-tech areas, entering new markets, deploying AI at scale, creating next-gen infrastructure, and realigning their workforce model.
Microsoft, which announced its layoffs on the second day of its 2026 fiscal year, asserted that it continues to implement organisational changes necessary to best position itself and teams for success in a dynamic marketplace. This was not the first time this year that the Redmond-based tech giant was announcing job cuts.
In January, the company announced it was laying off less than one per cent of its staff based on performance; in May, it cut over 6,000 jobs and 300 more in June. This is the biggest layoff by Microsoft since 2023, when it laid off over 10,000 of its staff. Microsoft is reportedly looking towards reducing the layers of middle managers between top executives and individual contributors.
Another notable development was Intel's decision to lay off over 5,000 of its workforce across four states in the US. The layoffs by Intel were not just limited to the US; some reports even suggested that the company was sacking staff from its branch in Israel.
In the US, most of the layoffs were reported from California and Oregon. Intel said that it was taking steps to become a leaner, faster, and more efficient company. CEO Lip-Bu Tan, after his takeover, has been prioritising Intel's core products for a new era of computing that is being defined by AI.
On July 10, Indeed and Glassdoor said that they were cutting about 1,300 jobs to move towards AI. The companies said that these cuts will impact their workforce in the US, in teams such as research development, people, and sustainability. While the company did not give any specific reason for the layoffs, in his memo CEO Hiyasuki Deko Idekoba said that AI is changing the world and that there was a need to adapt by ensuring that the company's products deliver truly great experiences.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
27 minutes ago
- Hindustan Times
FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud
MUMBAI: A 65-year-old businessman from Powai lost ₹52 lakh after an allegedly Japanese woman he befriended online convinced him to invest in Bitcoins and duped him in a cybercrime fraud for a month. The West Cyber police had initially received his complaint, and as the defrauded amount was less than ₹1 crore, they forwarded it to the Andheri police station, which registered a case against the woman and her accomplices on Saturday. From the last week of June to July 17, the victim invested ₹ 52 lakh.(HT File Photo) According to the complaint, the businessman received a Facebook friend request from an unknown person in June. The profile had a woman's photo and displayed her employment with IBM in Hong Kong. Believing it to be genuine, the complainant accepted her request, and the two began communicating through the messenger app. Also Read | Senior citizen loses ₹21 lakh to gaming fraud During their conversation, the accused asked for his mobile number, and the two began to speak with each other on the phone. Her soft-spoken manner on calls gained the complainant's trust, he said in the complaint. She told him she was currently working in an IBM office based in Hong Kong and that she would soon be joining the IBM Crypto trading platform in Japan as a manager. The complainant continued to talk with her for 10 more days about various subjects. She would tell him how investing in Bitcoin reaps huge profits and how it could benefit him. Though the complainant was initially reluctant, he was eventually convinced. Also Read | Businessman duped of ₹8.75 crore in a forex trading fraud Once the complainant expressed interest, she sent him a link and asked him to create an ID for his virtual account. He said he began investing money in Bitcoins through the bank accounts she provided. From the last week of June to July 17, he had invested ₹52 lakh. When he checked the application, it displayed ₹10.3 crore as his virtual bank account balance. Noticing huge returns, the 65-year-old wanted to, but could not invest more money in Bitcoins. So, he decided to withdraw the balance accumulated in his account. When he inquired about the withdrawal process, he was asked to pay a 30% tax first. Finding this suspicious, he discussed it with his relatives and realised he had been defrauded. Also Read | Fraud impersonates bizman's US-based brother, swindles ₹50k The complainant first contacted the Cyber Helpline number 1930 and filed a complaint. The Andheri police on Saturday registered a case under sections 66 (d) (dishonestly receiving stolen computer resource or communication device) of the Information Technology Act, 2000, and sections 318 (4) (cheating), 319 (2) (cheating by personation), 336 (2) and 336 (3) (forgery), 338 (forgery of valuable security documents), 340 (2) (using forged electronic document as genuine) and 61 (2) (criminal conspiracy) of the Bhartiya Nyaya Sanhita, 2023. 'We are trying to ascertain the identities of and trace the accused through the transactions made by the complainant,' said a police officer from Andheri police station.


Economic Times
30 minutes ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY


Time of India
43 minutes ago
- Time of India
China's Ant to exit Paytm in ₹3.8k cr deal
Mumbai: China's Ant Group will exit Paytm by selling its remaining 5.8% stake in the company through one or more block deals worth at least Rs 3,800 crore (about $434 million) on Tuesday, a term sheet showed. Tired of too many ads? go ad free now Ant Group (formerly Ant Financial), one of the early investors of the Noida-based fintech is an affiliate of Chinese tech giant Alibaba Group. After this deal, Paytm will have no Chinese ownership. Ant Group will sell about 3.7 crore shares in Paytm at a floor price of Rs 1,020 per share, a 5.4% discount to Paytm's closing price of Rs 1,078 on the NSE on Monday. Paytm declined to comment. Ant Group has been paring its exposure to the fintech - it sold a 4% in the company through block deals worth over Rs 2,000 crore in May this year. In 2023, Paytm founder Vijay Shekhar Sharma had bought a 10.3% stake in the firm worth $628 million from Ant Group to shore up his stake in the company and cut Chinese ownership. Alibaba had exited Paytm through a block deal in early 2023. "There's been a trend among Indian companies to reduce Chinese shareholding given the broader national sentiment," said an analyst on condition of anonymity. Sharma holds about a 9% stake in the firm, recent shareholding data showed. Paytm, which had come under regulatory scrutiny last year following RBI's move to wind down its banking unit due to non-compliance, swung back to profit in the June quarter. Over the past couple of years, SoftBank and Berkshire Hathaway exited Paytm. "From an investment standpoint, Ant Group perhaps doesn't see the same potential in Paytm compared to its first investment," independent fintech consultant Parijat Garg told TOI.